Ulcerative Proctitis

Case Study: Managing Ulcerative Proctitis with coMra Therapy

A 39-year-old male patient presented with a clinical history of ulcerative proctitis, characterized by bloody rectal discharge during defecation, often staining his undergarments. The patient noted that these symptoms were exacerbated by stress at home or in the workplace. Additional clinical symptoms included moderate pain preceding the urge to defecate, general malaise, weakness, and a diminished appetite. Due to his condition, the patient developed a fear of eating, which contributed to poor sleep quality and heightened irritability.

Clinical History and Previous Interventions

The patient had been living with this condition for over a year. Although he had been examined by a gastroenterologist and received formal medical recommendations, he had been inconsistent in following the prescribed treatment plan. His clinical records indicated that he underwent examinations only irregularly.

Over the course of his illness, the patient experienced a significant weight loss of 10 kilograms. While surgical intervention had been recommended by his medical team, the patient consistently refused this option. Furthermore, his adherence to prescribed medications remained poor. The diagnosis of ulcerative proctitis was formally confirmed through clinical diagnostic procedures, including an irigoscopy and a colonoscopy.

Treatment Progress with coMra Therapy

Upon initiating coMra therapy, the patient showed rapid improvement. Within three to four days of treatment, the pain preceding defecation subsided, his sleep quality improved, and his irritability decreased significantly.

Given the serious nature of the disease and its chronic, progressive course, the patient was advised to commit to a comprehensive treatment plan consisting of 25 sessions. To ensure sustained recovery, it was recommended that he take only short breaks of one to two weeks between treatment cycles. The objective was to maintain a consistent application of coMra therapy until a stable clinical and physical improvement was achieved. Once a state of stable remission is reached, the patient is advised to continue with maintenance treatments, administered one to two times per quarter, to support long-term health and prevent relapse.